GlaxoSmithKline News and Research

RSS

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

A viral respiratory infection common in children increases the risk of developing asthma

The study, published in The Journal of Infectious Diseases, is the first to show a link between respiratory syncytial virus, or RSV, infection and asthma in mice. A related study, also in mice, suggests that a medication neutralizing the virus could decrease children's chances of developing asthma.

28 Jun 2004

Drug companies spend about 37% of their overall R&D budgets on clinical affairs

Over the last decade, clinical services industry growth has exploded. Today, study sponsors dedicate significant portions of their budgets to CROs, SMOs and patient recruiters to access the expertise needed to speed trials to safe and successful fruition.

23 Jun 2004

New eye-tracking device

The newest research device at The William and Ida Friday Institute for Educational Innovation looks more like something out of a science fiction movie than a tool for discovering learning patterns.

21 Jun 2004

New York State accuses GlaxoSmithKline of fraudulent behaviour

This week's editorial calls on GlaxoSmithKline (GSK) to make all its research on paroxetine (Seroxat/Paxil) publicly available. This follows the filing of last week's law suit by the state of New York against GSK: the state accuses the company of fraud

11 Jun 2004

GlaxoSmithKline statement on spat with Spitzer

GlaxoSmithKline has acted responsibly in conducting clinical studies in pediatric patients and disseminating data from those studies. All pediatric studies have been made available to the FDA and regulatory agencies worldwide.

3 Jun 2004

Study shows herpes is common in suburban populations, with Denver up to 20 percent

According to a recent study of 36 primary care physician (PCP) offices in relatively affluent suburban areas of six U.S. cities, one in four people (25.5 percent) tested positive for the virus that causes genital herpes, despite the fact that only four percent of all those tested reported a history of the condition.

24 May 2004

Cystic Fibrosis Foundation Therapeutics awards $21 million to Vertex

Vertex Pharmaceuticals Incorporated has announced that it has expanded its drug discovery and development collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

24 May 2004

GlaxoSmithKline and Boehringer Ingelheim agree to assess the development of important HIV medicines for the developing world

GlaxoSmithKline plc and Boehringer Ingelheim announced today that both companies welcome the United States' continued involvement in the global response to HIV/AIDS.

17 May 2004

FDA approval of topical anti-inflammatory cream

Atrix Laboratories, Inc. has announced the company received approval from the U.S. Food and Drug Administration (FDA) to market fluticasone propionate cream.

15 May 2004

Researchers receive almost £1 million in funding for Irritable Bowel Syndrome

Researchers at The University of Nottingham, England have picked up almost £1 million in funding for a number of studies into a painful and distressing bowel condition that will affect up to one in 10 of the population at some time or another.

11 May 2004

What's the fourth biggest killer in America? Over 51% of Americans don't know either

More than half of Americans (51 percent) have never even heard of a disease that is the fourth leading killer in this country, according to results of a nationwide survey released today by the National Women’s Health Resource Center (NWHRC).

11 May 2004

The world generic drug market is expected to grow 10-15% annually

Currently, the world generic drug market is approaching $40 billion. Over the next five years, the market is expected to grow 10-15% annually.

6 May 2004

Estimates vary, but as much as 20% of new prescriptions never get filled and 85% of refills never leave the pharmacy

Furthermore, a study conducted by the University of Arizona's School of Pharmacy finds that 40% of patients who receive outpatient drug therapy will experience a treatment failure or new medical problem as a result of improper use.

28 Apr 2004

First generic cultivate(R) cream to receive tentative FDA approval

Atrix Laboratories, Inc. announced today the company received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for fluticasone propionate cream, 0.05%.

27 Apr 2004

GSK and WHO collaborate to fight malaria

GlaxoSmithKline (GSK), the World Health Organisation's Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria Venture (MMV) today announced the signing of a collaborative agreement, to develop a new-fixed dose artemisinin combination therapy drug (ACT), combining chlorproguanil, dapsone and artesunate (CDA) for the treatment of malaria.

23 Apr 2004

SSRI antidepressants may be unsuitable for children

A UK study in this week's issue of THE LANCET suggests that reliance on published studies alone to guide the treatment of childhood depression could be inappropriate. A systematic review including published and unpublished data shows that only one drug, fluoxetine (Prozac), was not associated with negative outcomes for children with depression.

22 Apr 2004